Literature DB >> 20841375

Knockdown of inwardly rectifying potassium channel Kir2.2 suppresses tumorigenesis by inducing reactive oxygen species-mediated cellular senescence.

Inkyoung Lee1, Chaehwa Park, Won Ki Kang.   

Abstract

Senescence is an important determinant of treatment outcome in cancer therapy. In the present study, we show that knockdown of the inwardly rectifying K(+) channel Kir2.2 induced growth arrest without additional cellular stress in cancer cells lacking functional p53, p16, and/or Rb. Kir2.2 knockdown also induced senescence-associated β-galactosidase activity and upregulated senescence marker proteins in multiple cancer cell lines derived from different tissues, including prostate, stomach, and breast. Interestingly, knockdown of Kir2.2 induced a significant increase in reactive oxygen species (ROS) that was accompanied by cell cycle arrest, characterized by significant upregulation of p27, with concomitant downregulation of cyclinA, cdc2, and E2F1. Kir2.2 knockdown cells displayed increased levels of PML bodies, DNA damage (γH2AX) foci, senescence-associated heterochromatin foci, mitochondrial dysfunction, secretory phenotype, and phosphatase inactivation. Conversely, overexpression of Kir2.2 decreased doxorubicin-induced ROS accumulation and cell growth inhibition. Kir2.2 knockdown-induced cellular senescence was blocked by N-acetylcysteine, indicating that ROS is a critical mediator of this pathway. In vivo tumorigenesis analyses revealed that tumors derived from Kir2.2 knockdown cells were significantly smaller than those derived from control cells (P < 0.0001) and showed a remarkable increase in senescence-associated proteins, including senescence-associated β-galactosidase, p27, and plasminogen activator inhibitor-1. Moreover, the preestablished tumors are reduced in size after the injection of siKir2.2 (P = 0.0095). Therefore, we propose for the first time that Kir2.2 knockdown induces senescence of cancer cells by a mechanism involving ROS accumulation that requires p27, but not Rb, p53, or p16. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20841375     DOI: 10.1158/1535-7163.MCT-10-0511

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  11 in total

Review 1.  Cellular physiological approach for treatment of gastric cancer.

Authors:  Atsushi Shiozaki; Daisuke Ichikawa; Eigo Otsuji; Yoshinori Marunaka
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

2.  An inhibitor of K+ channels modulates human endometrial tumor-initiating cells.

Authors:  Brandon M Schickling; Nukhet Aykin-Burns; Kimberly K Leslie; Douglas R Spitz; Victoria P Korovkina
Journal:  Cancer Cell Int       Date:  2011-08-02       Impact factor: 5.722

3.  Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy.

Authors:  Shengjie Guo; Feng Sun; Zhiyong Guo; Wei Li; Alan Alfano; Hegang Chen; Clara E Magyar; Jiaoti Huang; Toby C Chai; Shaopeng Qiu; Yun Qiu
Journal:  PLoS One       Date:  2011-03-07       Impact factor: 3.240

4.  Altered expression of two-pore domain potassium (K2P) channels in cancer.

Authors:  Sarah Williams; Andrew Bateman; Ita O'Kelly
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

5.  Membrane potential and cancer progression.

Authors:  Ming Yang; William J Brackenbury
Journal:  Front Physiol       Date:  2013-07-17       Impact factor: 4.566

Review 6.  Cancer as a channelopathy: ion channels and pumps in tumor development and progression.

Authors:  Alisa Litan; Sigrid A Langhans
Journal:  Front Cell Neurosci       Date:  2015-03-17       Impact factor: 5.505

Review 7.  Ion channels or aquaporins as novel molecular targets in gastric cancer.

Authors:  Jianling Xia; Hongqiang Wang; Shi Li; Qinghui Wu; Li Sun; Hongxiang Huang; Ming Zeng
Journal:  Mol Cancer       Date:  2017-03-06       Impact factor: 27.401

Review 8.  Physiological Significance of Ion Transporters and Channels in the Stomach and Pathophysiological Relevance in Gastric Cancer.

Authors:  Dumin Yuan; Zhiyuan Ma; Biguang Tuo; Taolang Li; Xuemei Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-12       Impact factor: 2.629

Review 9.  Potassium Channels as a Target for Cancer Therapy: Current Perspectives.

Authors:  Leandro Zúñiga; Angel Cayo; Wendy González; Cristian Vilos; Rafael Zúñiga
Journal:  Onco Targets Ther       Date:  2022-07-20       Impact factor: 4.345

10.  Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231.

Authors:  Mariel Núñez; Vanina Medina; Graciela Cricco; Máximo Croci; Claudia Cocca; Elena Rivera; Rosa Bergoc; Gabriela Martín
Journal:  BMC Pharmacol Toxicol       Date:  2013-01-11       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.